These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 19808957

  • 1. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
    Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.
    Cancer Res; 2009 Oct 15; 69(20):8085-93. PubMed ID: 19808957
    [Abstract] [Full Text] [Related]

  • 2. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr 15; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 3. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
    François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P.
    Cancer Res; 2009 May 15; 69(10):4335-45. PubMed ID: 19435913
    [Abstract] [Full Text] [Related]

  • 4. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 2000 Aug 15; 60(16):4499-506. PubMed ID: 10969798
    [Abstract] [Full Text] [Related]

  • 5. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N, Katoh N, Kitagawa T, Ueda E, Takenaka H, Kishimoto S.
    J Dermatol Sci; 2009 Apr 15; 54(1):31-7. PubMed ID: 19157789
    [Abstract] [Full Text] [Related]

  • 6. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R, Lau R, Chang J, Kuus-Reichel T, Brichard V, Bruck C, Weber J.
    Clin Cancer Res; 2004 Aug 01; 10(15):5004-13. PubMed ID: 15297401
    [Abstract] [Full Text] [Related]

  • 7. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
    Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, Romero P, Lejeune F, Liénard D, Speiser DE.
    Clin Cancer Res; 2003 Feb 01; 9(2):669-77. PubMed ID: 12576434
    [Abstract] [Full Text] [Related]

  • 8. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
    Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N.
    J Immunol; 2009 Oct 15; 183(8):5397-406. PubMed ID: 19786555
    [Abstract] [Full Text] [Related]

  • 9. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
    Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C, Romero P.
    Eur J Immunol; 2006 Jul 15; 36(7):1805-14. PubMed ID: 16761313
    [Abstract] [Full Text] [Related]

  • 10. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P.
    J Immunol; 2006 Nov 15; 177(10):6769-79. PubMed ID: 17082590
    [Abstract] [Full Text] [Related]

  • 11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Nov 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Dec 15; 161(12):6956-62. PubMed ID: 9862730
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.
    J Immunother; 2009 Dec 15; 32(6):613-21. PubMed ID: 19483648
    [Abstract] [Full Text] [Related]

  • 18. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N, Grenier AJ, Caty M, Charrier E, Duval A, Duval M, Champagne MA, Soudeyns H.
    J Immunol; 2010 Jul 15; 185(2):856-66. PubMed ID: 20543110
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.
    Cancer Res; 2003 Sep 01; 63(17):5601-6. PubMed ID: 14500401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.